|
|
| Illinois prisons approve new hepatits C drug for inmates, but not all to get it |
| By northwestern.edu- Jenn Stanley |
| Published: 05/22/2014 |
|
Only a small fraction of the state’s prison inmates infected with hepatitis C could likely receive a new highly effective treatment approved for use by the Illinois Department of Corrections. The Food and Drug Administration approved Gilead Sciences, Inc’s $1,000 per-pill “wonder drug,” Sovaldi, in December 2013. The decision by the IDOC sparked debate among state lawmakers, as one course of treatment costs about $84,000. Currently, anywhere between 2,500 and 3,700 Illinois prisoners have been diagnosed with hepatitis C, leaving many to question how the treatments will be financed. Read More. |
MARKETPLACE search vendors | advanced search
IN CASE YOU MISSED IT
|
Comments:
No comments have been posted for this article.
Login to let us know what you think